Abstract
Systemic and coronary hemodynamics and transmyocardial norepinephrine release were determined before and after oral administration of RO13-6438, a new inotrope-vasodilator agent, in 12 patients with severe chronic heart failure unresponsive to conventional and vasodilator therapy. improvement in left ventricular (LV) function was evident from a marked increase in cardiac index (from 2.09 ± 0.45 to 3.30 ± 0.73 liters/min/m2, p <0.01), stroke volume index (from 23 ± 7 to 36 ± 11 ml/m2, p <0.01), and stroke work index (from 23 ± 11 to 36 ± 14 g-m/m 2, p <0.01), and concomitant fall in pulmonary capillary wedge pressure (from 26 ± 7 to 16 ± 8 mm Hg, p <0.01). Myocardial oxygen consumption did not change significantly (from 15.3 ± 6.8 to 14.9 ± 6.8 mi/min), but the ratio of minute work/myocardial oxygen consumption, an index of LV efficiency, Increased significantly (p <0.05). Although average coronary sinus flow did not change, coronary sinus oxygen increased (from 3.2 ± 0.8 to 4.2 ± 1.5 vol%, p <0.05), and arterial-coronary sinus oxygen difference decreased (from 11.8 ± 2.1 to 10.4 ± 1.9 vol%, p <0.05), suggesting a primary vasodilating effect of R013-6438 on the coronary vascular bed. Net transmyocardial norepinephrine release did not change despite the marked hemodynamic improvement. These findings suggest that R013-6438 has the potential to cause marked improvement in LV function and LV efficiency in patients with severe, refractory congestive heart failure.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.